Clinical trial

Comparative Study on the Cognitive Function and Brain Imaging of Modified Suanzaoren Decoction and Eszopiclone in the Treatment of Primary Insomnia Patients With Yin Deficiency and Hyperactivity of Fire Syndrome

Name
2019MS08099
Description
The purpose of this study is to observe the cognitive function and clinical efficacy of modified Suanzaoren decoction and eszopiclone in the treatment of chronic insomnia disorder patients, and to investigate the possible neural mechanisms using MRI techniques.
Trial arms
Trial start
2020-09-10
Estimated PCD
2023-10-31
Trial end
2024-03-01
Status
Completed
Treatment
suanzaoren decoction
The Suanzaoren decoction is a Chinese herbal formula known for nourishing the blood, calming the mind, and nourishing the heart and liver
Arms:
suanzaoren decoction
Other names:
Suan Zao Ren Tang
Eszopiclone 1 mg
Eszopiclone is used in the treatment of various types of insomnia.
Arms:
eszopiclone
Other names:
Estorra
Size
85
Primary endpoint
The improvement of insomnia before and after treatment was assessed using the Pittsburgh Sleep Quality Index
4 weeks
Eligibility criteria
Inclusion Criteria: * Have adequate comprehension ability, with at least 9 years of education. * Western medical diagnosis criteria (meeting the diagnostic criteria for chronic insomnia disorder in ICSD-3). * Patient's subjective dissatisfaction with either the total duration or quality of sleep: difficulty falling asleep, difficulty maintaining sleep, or early awakening. * Frequency of sleep problems: occurring at least 3 nights per week, and persisting for at least 3 months. Exclusion Criteria: * Individuals who have used sedatives or hypnotics, or psychiatric medications in the week prior to enrollment. * Individuals who regularly consume strong tea, have a high smoking volume, or are dependent on coffee. * Women who are pregnant or breastfeeding. * Patients with severe primary diseases such as severe cardiovascular and cerebrovascular diseases, other mental disorders, or severe obstructive sleep apnea syndrome. * Individuals with allergies or multiple drug allergies.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 85, 'type': 'ACTUAL'}}
Updated at
2024-06-11

1 organization

2 products

1 indication

Indication
Insomnia